ClinicalTrials.gg
CompletedNCT05147233OPTIMIZE-1Updated Jul 11, 2025Results posted

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

A Phase 3 interventional study of OCS-01 and Vehicle in Inflammation Eye Pain and Postoperative Cataract, sponsored by Oculis. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Oculis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
241
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Enrollment
93rd of 322
241 · median 100
Started
2022
with 27 others
Phase 3
57 of 456
4 open now
Registered
329th of 456
by date

Among the 456 studies in Cataract with a site in United States, this one is the 93rd largest by enrollment of the 322 interventional ones that give a count, is one of 28 that started in 2022, is one of 57 in phase 3, and was the 329th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.

03

Conditions studied

  • Inflammation Eye Pain
  • Postoperative Cataract

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be planning to undergo unilateral cataract extraction via phacoemulsification and posterior chamber intraocular lens (PCIOL) implantation in the study eye.
  • Have a pin-hole visual acuity (VA) without any other correction > 20 letters (approximately 20/400) in the operative eye and > 35 letters (approximately 20/200) in the fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart at Visit 1 (Day -1 to Day -28 [prior to surgery]).

Exclusion criteria

Exclusion Criteria:

  • Have any intraocular inflammation (e.g. white blood cells or flare) present in either eye at the Visit 1 (Day -1 to Day -28 [prior to surgery]) slit lamp examination.
  • Have a score > 0 on the Ocular Pain Assessment at Visit 1 (Day -1 to Day -28 [prior to surgery]) in the study eye.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
241 participants (actual)

Study arms

  • Experimental
    OCS-01

    1 drop of OCS-01 (Dexamethasone ophthalmic suspension 1.5% \[15 mg/mL\]) in the study eye once daily (QD) for 14 days, beginning 1-day post-surgery in the study eye.

    Drug: OCS-01

  • Placebo comparator
    Vehicle

    1 drop of vehicle in the study eye QD for 14 days, beginning 1-day post-surgery in the study eye.

    Drug: Vehicle

Interventions

  • DrugOCS-01

    Dexamethasone ophthalmic suspension, 1.5%

  • DrugVehicle

    Vehicle

06

What researchers measure

Primary outcomes

  1. Absence of Anterior Chamber Cells at Visit 6.

    Time frame: Day 15

  2. Absence of Ocular Pain at Visit 4.

    Time frame: Day 4

07

Results

Posted Jul 11, 2025

Participant flow

Participant flow — Overall Study
MilestoneOCS-01Vehicle
Started119122
Completed116118
Not completed34
Withdrew: Adverse event01
Withdrew: Lost to follow-up11
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryAbsence of Anterior Chamber Cells at Visit 6.
Time frame:
Day 15
Reported as:
Number · percentage of study eyes
Absence of Anterior Chamber Cells at Visit 6.
percentage of study eyesOCS-01Vehicle
Absence of Anterior Chamber Cells at Visit 6.57.224.0
Statistical analysis
  • OCS-01 vs Vehicle · Wald test · p = <0.0001 · Difference in percentages: 33.2 · 95% CI 21.5 to 44.9
PrimaryAbsence of Ocular Pain at Visit 4.
Time frame:
Day 4
Reported as:
Number · percentage of study eyes
Absence of Ocular Pain at Visit 4.
percentage of study eyesOCS-01Vehicle
Absence of Ocular Pain at Visit 4.75.552.0
Statistical analysis
  • OCS-01 vs Vehicle · Wald test · p = <0.0001 · Difference in percentages: 23.5 · 95% CI 11.7 to 35.3

Adverse events

Collected over From first dose until Day 90. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OCS-010/119 (0%)0/119 (0%)2/119 (1.7%)
Vehicle0/122 (0%)1/122 (0.8%)8/122 (6.6%)
Most frequent serious events
Most frequent serious events
EventOCS-01Vehicle
Covid-19Infections and infestations0/1191/122
Most frequent other events
Most frequent other events
EventOCS-01Vehicle
Eye PainEye disorders2/1198/122

Baseline characteristics

The full analysis set (FAS) consists of all randomized subjects who were analyzed under the treatment to which they were randomized.

Age, Continuous
Age, Continuous(Years)OCS-01VehicleTotal
Mean68.8 ± 7.8067.8 ± 8.9868.3 ± 8.42
Sex: Female, Male
Sex: Female, Male(Participants)OCS-01VehicleTotal
Female7170141
Male4852100
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OCS-01VehicleTotal
Hispanic or Latino262652
Not Hispanic or Latino9396189
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OCS-01VehicleTotal
American Indian or Alaska Native101
Asian6511
Native Hawaiian or Other Pacific Islander000
Black or African American172542
White9591186
More than one race000
Unknown or Not Reported011
08

Study locations

25 sites
  • Oculis Site 16
    Chandler, Arizona 85224, United States
  • Oculis Site 28
    Phoenix, Arizona 85003, United States
  • Oculis Site 8
    Fayetteville, Arkansas 72704, United States
  • Oculis Site 9
    Inglewood, California 90301, United States
  • Oculis Site 23
    Newport Beach, California 92663, United States
  • Oculis Site 26
    Petaluma, California 94954, United States
  • Oculis Site 24
    San Pedro, California 90731, United States
  • Oculis Site 22
    Westminster, California 92683, United States
  • Oculis Site 11
    Fort Collins, Colorado 80528, United States
  • Oculis Site 12
    Tamarac, Florida 33321, United States
  • Oculis Site 17
    Morrow, Georgia 30260, United States
  • Oculis Site 20
    Louisville, Kentucky 40206, United States
  • Oculis Site 5
    St Louis, Missouri 63128, United States
  • Oculis Site 3
    Washington, Missouri 63090, United States
  • Oculis Site 13
    Kinston, North Carolina 28501, United States
  • Oculis Site 6
    Brecksville, Ohio 44141, United States
  • Oculis Site 14
    Cincinnati, Ohio 45242, United States
  • Oculis Site 25
    Eugene, Oregon 97401, United States
  • Oculis Site 7
    Kingston, Pennsylvania 18704, United States
  • Oculis Site 4
    Austin, Texas 78731, United States
  • Oculis Site 10
    Houston, Texas 77025, United States
  • Oculis Site 2
    San Antonio, Texas 78229, United States
  • Oculis Site 31
    San Antonio, Texas 78229, United States
  • Oculis Site 27
    Salt Lake City, Utah 84032, United States
  • Oculis Site 30
    Lynchburg, Virginia 24502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jun 2023, 11 months.

Results were first posted in Jul 2025, 2 years after primary completion.

Of 23 industry-sponsored phase 3 interventional studies under Cataract, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 15. This study's 11 months is close to that.

Counting every sponsor, half of 31 studies reached it within 13 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2021
First posted
Dec 7, 2021
StartActual
Jun 24, 2022
Primary completionActual
Jun 22, 2023
CompletionActual
Jul 3, 2023
Results first posted
Jul 11, 2025
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05147233
Lead sponsor
Oculis
Responsible party
Sponsor
First posted
Dec 7, 2021
Start date
Jun 24, 2022
Primary completion
Jun 22, 2023
Completion
Jul 3, 2023
Results posted
Jul 11, 2025
Last update
Jul 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OCS-01

Start the discussion